UPenn researchers find that blocking autophagy with malaria drug may help overcome resistance to melanoma BRAF drugs
- Posted: February 25, 2014
A new preclinical study published online ahead of print in the Journal of Clinical Investigation from Penn Medicine researchers found that the root of BRAF drug resistance may lie in a never-before-seen autophagy mechanism induced by the BRAF inhibitors vermurafenib and dabrafenib.
Click here to read the full press release.
Among the research institutions NCI funds across the United States, it currently designates 68 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.